Taming the Medical Literature ~ For Genetic Conditions ~ Hand-Curated • Direct to You
LitAlert ~~ GeneLit.com
The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM, Mann RM, Loo CCE, Lobbes M, Voormolen EMC, van Deurzen CHM, de Bock G, Hereditary Breast Ovarian Cancer Research Group Netherlands (HEBON), Hooning MJ.
Breast Cancer Res Treat. 2020 Apr 24. doi: 10.1007/s10549-020-05642-1. [Epub ahead of print]
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R, Hall M, Lofts F, Glasspool RM, Hudson E.
Int J Gynecol Cancer. 2020 Apr 21. pii: ijgc-2019-000973. doi: 10.1136/ijgc-2019-000973. [Epub ahead of print]
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, Teule A, Brunet J, Y Cajal TR, Llort G, Dienstmann R, Rue M, Domchek SM, Balmaña J.
Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.
Wappenschmidt B, Hauke J, Faust U, Niederacher D, Wiesmüller L, Schmidt G, Groß E, Gehrig A, Sutter C, Ramser J, Rump A, Arnold N, Meindl A.